Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results Back to the Newsroom Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results TAAPTM (Opioid Abuse Deterrent) Program Update Ensysce's lead drug candidate, PF614, is a Trypsin-Activated Abuse Protection (TAAPTM) extended-release oxycodone designed to deliver effective pain relief while incorporating built-in abuse protection. Through proprietary chemical modification of ox ...

As filed with the Securities and Exchange Commission on November 17, 2023 Registration No. 333-275456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENSYSCE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Delaware 2834 82-2755287 (I.R.S. Employer Identification Number) 79 ...

(State or Other Jurisdiction of Incorporation or Organization) As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. 333-****** UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENSYSCE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 2834 82-2755287 (I.R.S. Employer Identification Number) 7946 Iva ...